The role of ointment base on stability of dexketoprofen trometamol in ointments

Year 2021, Volume: 25 Issue: 5, 681 - 688, 28.06.2025

Gülen Melike Demirbolat , Abdurrahman Demirel

Abstract

The stability of the active pharmaceutical ingredients (API) and the final product is one of the most important factors in the design and development of drug forms. The storage conditions stated on the product label arise from the evaluation of the scientific data extracted from stability studies. In this study, the effect of ointment base excipients on stability was conducted, besides the effect of freeze-thaw tests on product stability. Dexketoprofen trometamol which is a highly soluble active substance in the water was selected as a model drug within the scope of this study. It was formulated as a semi-solid dosage form with different types of bases (an oil-based, a water-based, and emulsion-based ointment excipients). The stability tests in long-term and accelerated conditions were performed on each product at certain periods. The commercial product of dexketoprofen trometamol (Dexalgin gel) was also evaluated. The loss of API in the ointment with high oil content was higher than the others in both long term and accelerated stability test conditions. The active ingredient loss was higher than 5% even after the first freeze-thaw process for all formulation including commercial product in gel form. After two cycle-freeze-thaw processes, the amount of API was dramatically changed (from 18% of degradation in even commercial gel products, which were the most stable formulation in this study). It was presented that freeze-thaw processes were much more crucial than the two-month storage in high temperatures (i.e. 40°C).

Keywords

Stability , dexketoprofen trometamol , semi-solid products , topical formulations , freeze-thaw

References

• [1] Wong AW, Datla A. 13 - Assay and stability testing. In: Ahuja S, Dong M (Eds.). Handbook of Pharmaceutical Analyses by HPLC. Academic Press, 2005, pp. 335–358.
• [2] Dib SA. MS Thesis. Stability of phenylephrine hydrochloride in polyvinyl chloride bags. Dentistry, The Ohio State University, United States of America, 2019.
• [3] Kommanaboyina B, Rhodes CT. Trends in stability testing, with emphasis on stability during distribution and storage. Drug Dev Ind Pharm. 1999; 25: 857–868.
• [4] Tangri P, Bisht B. Who role and guidelines in stability study of pharmaceuticals: a regulatory perspective. Int J Res Pharm Biomed Sci. 2012; 3: 1379–1386.
• [5] Huynh-Ba K. Handbook of stability testing in pharmaceutical development: regulations, methodologies, and best practices, 2009th ed., Springer Science & Business Media, NJ, USA, 2008.
• [6] European Medicines Agency, ICH Topic Q 1 A (R2) Stability testing of new drug substances and products, (2003) 1– 20 https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug- substances-products-step-5_en.pdf , (accessed June 2, 2021).
• [7] Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs—A review. J Pharm Anal. 2014; 4: 159–165. Research Article [8] World Health Organization, Technical Report Series, Annex 10 Stability testing of active pharmaceutical ingredients and finished pharmaceutical products, (2009) 309–352, https://www.who.int/medicines/publications/pharmprep/WHO_TRS_996_annex10.pdf, (accessed June 2, 2021).
• [9] Pimple S, Maurya P, Salunke K, Singh R, Gurjar M, Shah M. Formulation development and compatibility study of dexketoprofen injection used in the management of post-operative pain. Int J Pharm Sci Rev Res. 2015; 30(1): 299– 305.
• [10] Garcia-Arieta A, Gordon J, Gwaza L, Mangas-Sanjuan V, Álvarez C, Torrado JJ. Agitation rate and time for complete dissolution in BCS biowaivers based on investigation of a BCS biowaiver for dexketoprofen tablets. Mol Pharm. 2015; 12: 3194–3201.
• [11] Bhusari VK, Dhaneshwar SR. Application of a stability-indicating Tlc method for the quantitative determination of dexketoprofen trometamol in pharmaceutical dosage forms. J Liq Chromatogr Relat Technol. 2011; 34: 2606–2620.
• [12] USP 31/NF 26, The United States Pharmacopeial Convention, Inc. Chapter 〈1151〉. Rockville, 2007.
• [13] De Villiers M. Ointment bases. In: Thompson JE. (Eds). A Practical Guide to Contemporary Pharmacy Practice Lippincott Williams & Wilkins, Pennsylvania, 2009, pp. 277–290.
• [14] Matthews BR. Regulatory aspects of stability testing in Europe. Drug Dev Ind Pharm. 1999; 25: 831–856.
• [15] Schaut RA, Weeks WP. Historical review of glasses used for parenteral packaging. PDA J Pharm Sci Technol. 2017; 71: 279–296.
• [16] Bajaj S, Singla D, Sakhuja N. Stability testing of pharmaceutical products. J Appl Pharm Sci. 2012; 2: 129–138.
• [17] Loftsson T, Ilievska B, Asgrimsdottir GM, Ormarsson OT, Stefansson E. Fatty acids from marine lipids: Biological activity, formulation and stability. J Drug Deliv Sci Technol. 2016; 34: 71–75.
• [18] Gousia Begum S, Chetty CM, Pavithra B, Akhila B, Gayathri C, Ruksar S, Sravani T, Voleti VK. A review on emulgels- a novel approach for topical drug delivery. Asian J Pharm Res Dev. 2019; 7: 70–77.
• [19] Pérez D, Paz N, Fernández Cervera M, Mantilla N, Peña M, Menéndez A, Garrido G. Optimization, physical-chemical evaluation and healing activity of chitosan ointment. J Pharm Pharmacogn Res. 2019; 7: 297–309.
• [20] Chang RK, Raw A, Lionberger R, Yu L. Generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatologic products. AAPS J. 2013; 15: 41–52.
• [21] El-Malla S. Spectroscopic methods for determination of dexketoprofen trometamol and tramadol HCl. Inven Impact Pharm Anal Qual Assur. 2014; 4: 276–282.